Loading
Below, week by week, is what OnCo's record of Indolent and smouldering systemic mastocytosis says about the first two months: the order is typical, the timing is yours to ask about. Indolent systemic mastocytosis is the common, slow form of this rare blood disorder, in which KIT-mutant mast cells build up in the marrow and skin and release histamine that causes flushing, itching, stomach pain, bone thinning and sometimes severe allergic reactions. Life expectancy is near normal, antihistamines and adrenaline control symptoms, and low-dose avapritinib was approved in 2023. Sections appear only where the record has something to say. Orientation, not medical advice.
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Serum tryptase, KIT D816V testing in peripheral blood, bone marrow biopsy with flow cytometry, tryptase gene copy number, bone density scan and screening for B and C findings.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
H1 and H2 antihistamines, cromoglicate, leukotriene antagonists, proton-pump inhibitors; omalizumab for recurrent anaphylaxis; adrenaline autoinjectors for all; venom immunotherapy after sting anaphylaxis; bisphosphonates for osteoporosis.
Elenestinib (HARBOR) and bezuclastinib (Summit) as more selective KIT D816V inhibitors.
Tryptase, KIT allele burden and blood count yearly; bone density; marrow re-examination only if progression is suspected.
Avapritinib 25 mg daily (PIONEER, approved 2023), avoided when platelets are below 50 x 10^9/L; cladribine or interferon alfa as older cytoreductive options.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
Every term links to the glossary.